CardiologyComparative Effectiveness of Prasugrel Versus Clopidogrel in Patients with Impaired Renal Function: A Clinical Review
MedXY Editorial Team
Highlights
- Prasugrel achieves faster and more significant early platelet aggregation reduction than clopidogrel in patients with eGFR < 45 mL/min/1.73 m2.
- The differential efficacy of antiplatelet agents emerges primarily within the first five days of treatment initiation.
- Both prasugrel and clopidogrel maintain a favorable safety profile with respect to bleeding risk across renal function strata.
- Renal impairment influences early pharmacodynamic response to P2Y12 inhibitors, emphasizing tailored antiplatelet therapy.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
